LevEllis

What LevEllis does

LevEllis is a regenerative aesthetics company founded in 2024 and headquartered in Asheville, North Carolina, that markets PROVOQUE, a single anti-aging facial serum built around a 'complete skin secretome' derived from human skin progenitor cells. The proprietary formulation combines peptides, growth factors, exosomes, and fetuin-A — claimed to be exclusive to PROVOQUE — and is clinically supported by a peer-reviewed study in the Journal of Drugs in Dermatology documenting visible results in as little as 14 days, statistically significant results at 4 weeks, continued improvement through 12 weeks, and a 25% collagen increase verified by biopsy. The core technology and active-ingredient manufacturing are licensed exclusively worldwide from AIVITA Biomedical under an October 2024 agreement.

The company is co-founded by Dr. Laura Ellis, MD, a pioneer in aesthetic medicine who serves as CEO, and Dr. Hans Keirstead, a stem cell scientist; leadership credibility is reinforced by endorsements from dermatology key opinion leaders such as Mary P. Lupo, MD. Distribution runs through a hybrid go-to-market: direct-to-consumer e-commerce via myprovoque.com and a professional provider network (the Find A Provider / Become A Provider channel) targeting dermatologists, plastic surgeons, and aesthetic-medicine practitioners who dispense PROVOQUE to patients. Larger orders and investor inquiries are handled via a single inbound email ([email protected]).

Revenue mechanics rely on product sales only, with no publicly disclosed pricing tiers or subscription plans; the company is privately held (LLC), reports 1–10 employees, and filed an SEC Form D exempt offering of up to $4 million (with $1.15M recorded as raised in the June 2024 tranche). The product was officially launched on July 10, 2025, and LevEllis has emphasized earned-media placements (Stylish Magazine, Peter Diamandis' Abundance Longevity platform, and the Plastic Surgery Untold podcast) alongside website and newsletter content marketing. All revenue depends on the commercial performance of one formulation under one technology license; there are no disclosed subscription, SaaS, or data-products revenue streams.

Name

LevEllis

Legal name

LevEllis

Website

https://levellis.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

LevEllis is a North Carolina-based regenerative aesthetics company founded in 2024 that exclusively markets PROVOQUE, an anti-aging facial serum built on a proprietary complete-skin-secretome technology licensed from AIVITA Biomedical, sold direct-to-consumer and through a professional provider network of dermatologists and aesthetic practitioners.

Ownership category

akta.pro rank

Product category

Regenerative Anti-Aging Skincare

NAICS

Cosmetics, Beauty Supplies, and Perfume Retailers (45612)

SIC

Perfumes, Cosmetics & Other Toilet Preparations (2844)

akta.pro primary industry

Treatment Skincare (Serums, Actives, Acne & Anti-aging) (CRABAAAB)

akta.pro secondary industries

Dermocosmetics & Medical-Grade Skincare (CRABAAAF), Professional/Backbar Skincare (Esthetician & Spa Use) (CRABAAAK)

Keywords

• Regenerative skincare
• Anti-aging serum
• Skin secretome
• Growth factor skincare
• Exosome cosmetics

Headquarters

HQ city

Asheville

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Marketing or Sales, Personnel, Technology or R&D, Operations

Revenue model

1. PROVOQUE Skincare Product Sales: LevEllis generates revenue through the sale of PROVOQUE regenerative skincare serum. The product is sold via direct-to-consumer e-commerce through the company's website (myprovoque.com) and through professional channels where dermatologists and aesthetic practitioners dispense the product to patients. Revenue is primarily product-based (one-time purchase model for consumer units), with potential for recurring professional repurchase.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

LevEllis sells PROVOQUE™, a topical regenerative anti-aging facial serum powered by proprietary complete skin secretome technology derived from human skin progenitor cells. The serum delivers a full spectrum of regenerative signaling molecules—growth factors, exosomes, fetuin-A, and peptides—in a single formula, targeting both end consumers via direct-to-consumer e-commerce and dermatology/aesthetic practices via a professional provider network.

Product overview

LevEllis is a single-product company focused on regenerative aesthetics. The company offers PROVOQUE™, a topical regenerative skincare serum that represents the core and only product offering. The product leverages proprietary secretome technology licensed from AIVITA Biomedical, derived from human skin progenitor cells. PROVOQUE is positioned as a premium anti-aging solution distributed through dermatologists and aesthetic providers.

Differentiator

Problem solved

Functional benefit

Brands

• PROVOQUE: A breakthrough anti-aging facial serum powered by the complete skin secretome, including growth factors, exosomes, and fetuin-A.

Products and services

• PROVOQUE™ A breakthrough anti-aging facial serum powered by the complete skin secretome. Delivers a complete skin-specific secretome matrix including growth factors, exosomes, fetuin-A, and other regenerative molecules. Clinically validated to show visible results in as little as 14 days, with statistically significant improvements in 4 weeks and continued improvement through 12 weeks. Distributed to end consumers through DTC e-commerce and through dermatologists and aesthetic practitioners.

Quantifiable outcome

• 25% increase in collagen (verified by biopsy)
• +3 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• AIVITA BiomedicalcoreOEM/ Whitelabel/ Licensing Partner · 1 October 2024LevEllis secured exclusive worldwide rights to market and distribute PROVOQUE formulations through a licensing agreement with AIVITA Biomedical signed in October 2024. Under the agreement, AIVITA continues to manufacture the active ingredients from its FDA-registered facility in the USA. This is a foundational partnership providing the core technology and manufacturing for LevEllis's lead product.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• SkinMedica: SkinMedica (owned by Allergan Aesthetics / AbbVie) is a leading professional skincare brand featuring growth-factor and regenerative anti-aging serums dispensed through dermatologists and aesthetic practices — directly comparable to PROVOQUE's provider-channel distribution and science-led positioning.
• EltaMD: EltaMD (owned by Colgate-Palmolive) is a medical-grade skincare brand with broad distribution through dermatologists, plastic surgeons, and medspas — a broad incumbent comparable to PROVOQUE in provider-dispensed positioning and clinical-framed messaging.

Direct peers

• Alastin Skincare: Alastin Skincare (a Galderma company) is a regenerative aesthetics brand built around proprietary TriHex Technology, sold primarily through plastic surgeons, dermatologists, and medical spas — the closest direct peer to PROVOQUE in science-backed, provider-dispensed anti-aging skincare.
• iS Clinical: iS Clinical is a cosmeceutical brand offering active-treatment serums marketed to physicians, spas, and consumers, with clinically validated anti-aging claims — directly comparable to PROVOQUE in formulation philosophy and hybrid professional/DTC distribution.
• PCA Skin: PCA Skin is a professional skincare company offering treatment serums and chemical peels dispensed through licensed skincare professionals and sold DTC — directly comparable to PROVOQUE in target customer, product format, and channel mix.
• ZO Skin Health: ZO Skin Health, founded by Dr. Zein Obagi, is a physician-dispensed skincare line built around proprietary active regimens for anti-aging and skin health — directly comparable to PROVOQUE in provider-channel anti-aging positioning and clinical credibility emphasis.
• Jan Marini Skin Research: Jan Marini Skin Research is a science-driven cosmeceutical brand offering treatment serums and anti-aging systems sold through physicians and DTC — comparable to PROVOQUE in active-serum focus, evidence-based claims, and hybrid professional/consumer channels.

Emerging players

• AnteAGE: AnteAGE markets growth-factor and cytokine-based regenerative skincare serums to medical providers and consumers — an emerging direct competitor to PROVOQUE's secretome approach, with overlapping science narrative and provider-channel distribution.
• Plated Skin Science: Plated Skin Science sells exosome-based serums targeting anti-aging and skin rejuvenation, marketed through dermatologists and DTC — directly comparable to the exosome component of PROVOQUE and a likely head-to-head competitor in the regenerative category.
• Calecim Professional: Calecim Professional markets stem-cell-derived growth factor serums for post-procedure and anti-aging use, dispensed through aesthetic clinics — an emerging peer overlapping PROVOQUE on stem-cell-derived regenerative actives and provider distribution.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LevEllis